No Data
No Data
Workshop of Shuangcheng Pharma's Unit Passes Regulatory Inspection; Shares Up 3%
A production line of Ningbo Shuangcheng Pharmaceutical, a unit of Hainan Shuangcheng Pharmaceutical (SHE:002693), passed the good manufacturing practices or GMP inspection of the drug regulator in Chi
Shuangcheng Pharmaceutical (002693.SZ): Ningbo Shuangcheng Oral Solids Workshop 1, capsule production line passed GMP compliance inspection
Gelonghui, May 21丨Shuangcheng Pharmaceutical (002693.SZ) announced that the company's holding subsidiary, Ningbo Shuangcheng Pharmaceutical Co., Ltd. (“Ningbo Shuangcheng”), learned from the Zhejiang Drug Administration website that Ningbo Shuangcheng Oral Solids Workshop 1. The capsule production line passed the GMP compliance inspection.
Zhitong A Share Sale Restriction Release List|May 13
According to the Zhitong Finance App, the ban on restricted shares of 30 listed companies was lifted on May 13, with a total market value of about 23.962 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Harbin Pharmaceutical shares 600664, share incentives, 1,531,000 Weixing shares 002003, share incentives, limited circulation, 6.942 million Lianchuang Electronics 002036, equity incentives, 5.651 million, Longyuan Technology 300105 share incentives, limited sales, circulation, 1.4411 million, Huapengfei 300350 share incentive circulation 220,08 Wan Jin Rongtian
Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US
Hainan Shuangcheng Pharmaceutical (SHE:002693) obtained marketing authorization from the US Food and Drug Administration for its octreotide acetate injection, according to a filing with the Shenzhen S
Shuangcheng Pharmaceutical (002693.SZ): Octreotide acetate injection ANDA obtained US FDA marketing approval
Gelonghui, May 6, 丨 Shuangcheng Pharmaceutical (002693.SZ) announced that the company recently received a notice from the US Food and Drug Administration (“FDA”). The simplified new drug application for octreotide acetate injection submitted by the company to the US FDA (“ANDA” for short) has been approved for marketing by the US FDA. The US FDA conducted a comprehensive technical review of the ANDA application data for octreotide acetate injection submitted by the company, and approved the comprehensiveness and scientific nature of the application information. Octreotide acetate injection is suitable for patients with acromegaly whose condition cannot be adequately controlled by controlled surgery or radiation therapy
Shuangcheng Pharmaceutical (002693.SZ): Net loss of 8.7427 million yuan in the first quarter
Gelonghui, April 29 | Shuangcheng Pharmaceutical (002693.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 42.7617 million yuan, a year-on-year decrease of 47.52%; net profit attributable to shareholders of listed companies - 8.7427 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 9.0527 million yuan; basic earnings per share - 0.0211 yuan.
No Data